Short Interest in Aclarion, Inc. (NASDAQ:ACON) Rises By 379.3%

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 148,674 shares, an increase of 379.3% from the December 31st total of 31,021 shares. Approximately 17.6% of the shares of the company are short sold. Based on an average daily trading volume, of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days. Approximately 17.6% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ACON. Wall Street Zen upgraded Aclarion to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Aclarion Stock Down 1.1%

Aclarion stock opened at $3.64 on Wednesday. The stock has a market cap of $3.09 million, a price-to-earnings ratio of -0.24 and a beta of 1.44. The business has a 50-day simple moving average of $5.47 and a 200 day simple moving average of $6.80. Aclarion has a 52 week low of $3.61 and a 52 week high of $562.68.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) EPS for the quarter, missing the consensus estimate of ($2.64) by ($0.29). Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%.The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, research analysts anticipate that Aclarion will post -263.33 earnings per share for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.